Business Context and Reporting Period
This Form 8-K filing by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) covers events occurring on May 9, 2017, with the report dated May 11, 2017. The filing addresses corporate governance changes, specifically the resignation of a director and the election of a new director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on director compensation arrangements:
- Resignation Compensation: Accelerated vesting of an option for 500 shares and extension of the exercise period through May 9, 2019, for options covering 2,625 total shares previously awarded to the departing director.
- New Director Compensation: Annual retainer of $15,000, meeting fees of $1,000 (in-person) or $500 (telephone), and an initial stock option to purchase 1,125 shares vesting over three years.
Material Changes
The primary material change is the composition of the Board of Directors:
- Resignation: Andrew K. Rooke resigned effective May 9, 2017. The resignation was voluntary and not the result of any disagreement with the company.
- Election: R. John Fletcher was elected as a new director effective May 9, 2017, to serve until the 2017 annual meeting of stockholders.
Outlook, Risks, and Management Commentary
Management commentary indicates the transition was strategic, intended to bring R. John Fletcher's extensive public company board experience and healthcare industry focus to the Board. No financial risks, contingencies, or unusual items were disclosed in this filing. The company entered into a standard indemnification agreement with the new director.
Investor Verification Checklist
- Verify the exact number of shares subject to the accelerated vesting and extended exercise period for the departing director.
- Confirm the vesting schedule and grant date for the new director's initial stock option.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the board change.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.